By Amelia Bott
CSL’s reinvestment in the business at high rates of return contributes to CSL’s strong intrinsic value growth of 16. 3 per cent in fiscal 2015.
CSL’s R&D investment is expected to grow 13 per cent in fiscal 2014.
Global demand for its core products, immunoglobulin and albumin remain robust and CSL’s historical investment in capacity makes it well-positioned to benefit from growing demand.
CSL’s profitability, as measured by return on equity, has averaged 33 per cent over the last five years and has benefitted from CSL’s ongoing buybacks.
Read more here: Business Spectator